EA201891979A1 - Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 - Google Patents
Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3Info
- Publication number
- EA201891979A1 EA201891979A1 EA201891979A EA201891979A EA201891979A1 EA 201891979 A1 EA201891979 A1 EA 201891979A1 EA 201891979 A EA201891979 A EA 201891979A EA 201891979 A EA201891979 A EA 201891979A EA 201891979 A1 EA201891979 A1 EA 201891979A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- pcsk9
- methods
- combination
- angptl3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к способам лечения пациентов, страдающих гиперхолестеринемией, где пациент невосприимчив к, не достигает адекватного контроля или не переносит лечение стандартной липидмодифицирующей терапией. Способы по изобретению обеспечивают снижение по меньшей мере одного показателя липидного обмена у пациента введением терапевтически эффективного количества антитела или его антигенсвязывающего фрагмента, которые специфически связываются с пропротеинконвертазой субтилизин/кексинового типа 9 (PCSK9) в комбинации с терапевтически эффективным количеством антитела, которое специфически связывается с ангиопоэтинподобным белком 3 (ANGPTL3). Комбинация анти-PCSK9-антитела с анти-ANGPTL3-антителом пригодна для лечения таких заболеваний, как гиперхолестеринемия, включая семейную гиперхолестеринемию (FH), как heFH, так и hoFH, а также гиперлипидемия, гиперлипопротеинемия и дислипидемия, включая гипертриглицеридемию, хиломикронемию, и для профилактики или лечения заболеваний или расстройств, для которых аномальный липидный обмен является фактором риска, таким как фактор риска развития сердечно-сосудистых заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662302907P | 2016-03-03 | 2016-03-03 | |
PCT/US2017/020221 WO2017151783A1 (en) | 2016-03-03 | 2017-03-01 | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891979A1 true EA201891979A1 (ru) | 2019-01-31 |
Family
ID=58361088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891979A EA201891979A1 (ru) | 2016-03-03 | 2017-03-01 | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20170253666A1 (ru) |
EP (1) | EP3423157A1 (ru) |
JP (3) | JP2019512472A (ru) |
KR (1) | KR102456731B1 (ru) |
CN (1) | CN109069868B (ru) |
AU (1) | AU2017227713B2 (ru) |
CA (1) | CA3016764A1 (ru) |
EA (1) | EA201891979A1 (ru) |
IL (1) | IL261420A (ru) |
MA (1) | MA43734A (ru) |
MX (1) | MX2018010401A (ru) |
WO (1) | WO2017151783A1 (ru) |
ZA (1) | ZA201805403B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
EP3993820A4 (en) * | 2019-07-04 | 2023-08-16 | Cadila Healthcare Limited | VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES |
WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
US10544232B2 (en) * | 2014-07-16 | 2020-01-28 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody |
-
2017
- 2017-03-01 CN CN201780014857.0A patent/CN109069868B/zh active Active
- 2017-03-01 US US15/446,720 patent/US20170253666A1/en not_active Abandoned
- 2017-03-01 KR KR1020187028068A patent/KR102456731B1/ko active IP Right Grant
- 2017-03-01 EP EP17712283.5A patent/EP3423157A1/en active Pending
- 2017-03-01 JP JP2018545828A patent/JP2019512472A/ja active Pending
- 2017-03-01 CA CA3016764A patent/CA3016764A1/en active Pending
- 2017-03-01 EA EA201891979A patent/EA201891979A1/ru unknown
- 2017-03-01 AU AU2017227713A patent/AU2017227713B2/en active Active
- 2017-03-01 MX MX2018010401A patent/MX2018010401A/es unknown
- 2017-03-01 WO PCT/US2017/020221 patent/WO2017151783A1/en active Application Filing
- 2017-03-01 MA MA043734A patent/MA43734A/fr unknown
-
2018
- 2018-08-14 ZA ZA2018/05403A patent/ZA201805403B/en unknown
- 2018-08-28 IL IL261420A patent/IL261420A/en unknown
-
2020
- 2020-03-03 US US16/808,058 patent/US20200199253A1/en active Pending
-
2022
- 2022-03-16 JP JP2022040874A patent/JP2022078306A/ja active Pending
-
2024
- 2024-02-22 JP JP2024025078A patent/JP2024059787A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201805403B (en) | 2019-08-28 |
IL261420A (en) | 2018-10-31 |
KR20180118181A (ko) | 2018-10-30 |
US20170253666A1 (en) | 2017-09-07 |
CN109069868A (zh) | 2018-12-21 |
JP2024059787A (ja) | 2024-05-01 |
KR102456731B1 (ko) | 2022-10-24 |
US20200199253A1 (en) | 2020-06-25 |
MA43734A (fr) | 2018-11-28 |
WO2017151783A1 (en) | 2017-09-08 |
AU2017227713A1 (en) | 2018-09-13 |
CN109069868B (zh) | 2023-06-06 |
JP2019512472A (ja) | 2019-05-16 |
EP3423157A1 (en) | 2019-01-09 |
MX2018010401A (es) | 2019-03-06 |
JP2022078306A (ja) | 2022-05-24 |
CA3016764A1 (en) | 2017-09-08 |
AU2017227713B2 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012221A (es) | Metodos para tratar hiperlipidemia con un inhibidor de proteina tipo angiopoyetina 8 y un inhibidor de proteina tipo angiopoyetina 3. | |
EA201891979A1 (ru) | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 | |
Marshansky et al. | Sleep, chronic pain, and opioid risk for apnea | |
MX2018012741A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. | |
EA201590370A1 (ru) | Антитела к pcsk9 c ph-зависимыми характеристиками связывания | |
MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
EA200501560A1 (ru) | Предотвращение и терапия амилоидогенной болезни | |
EA201892218A1 (ru) | Способы ингибирования ангиогенеза у пациента | |
MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
WO2011066378A3 (en) | Antagonists of il-6 to prevent or treat thrombosis | |
AR087329A1 (es) | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana | |
HRP20230992T1 (hr) | Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3 | |
MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
EA202092154A1 (ru) | Комбинированная терапия | |
CY1111478T1 (el) | Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης | |
MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
Yang et al. | Enhanced antidepressant-like effects of electroacupuncture combined with citalopram in a rat model of depression | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
MX2021009413A (es) | Materiales y métodos para tratar una enfermedad neurodegenerativa. |